AU2012351939A1 - Angiotensins for treatment of fibrosis - Google Patents

Angiotensins for treatment of fibrosis Download PDF

Info

Publication number
AU2012351939A1
AU2012351939A1 AU2012351939A AU2012351939A AU2012351939A1 AU 2012351939 A1 AU2012351939 A1 AU 2012351939A1 AU 2012351939 A AU2012351939 A AU 2012351939A AU 2012351939 A AU2012351939 A AU 2012351939A AU 2012351939 A1 AU2012351939 A1 AU 2012351939A1
Authority
AU
Australia
Prior art keywords
angiotensin
analog
fibrosis
derivative
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012351939A
Other languages
English (en)
Inventor
Paul BERINGER
Richard Franklin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Tarix Pharmaceuticals Ltd
Original Assignee
University of Southern California USC
Tarix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC, Tarix Pharmaceuticals Ltd filed Critical University of Southern California USC
Publication of AU2012351939A1 publication Critical patent/AU2012351939A1/en
Assigned to UNIVERSITY OF SOUTHERN CALIFORNIA, TARIX PHARMACEUTICALS LTD. reassignment UNIVERSITY OF SOUTHERN CALIFORNIA Amend patent request/document other than specification (104) Assignors: TARIX PHARMACEUTICALS LTD.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Reinforced Plastic Materials (AREA)
AU2012351939A 2011-12-16 2012-12-14 Angiotensins for treatment of fibrosis Abandoned AU2012351939A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161576673P 2011-12-16 2011-12-16
US61/576,673 2011-12-16
US201161579936P 2011-12-23 2011-12-23
US61/579,936 2011-12-23
PCT/US2012/069930 WO2013090833A1 (en) 2011-12-16 2012-12-14 Angiotensins for treatment of fibrosis

Publications (1)

Publication Number Publication Date
AU2012351939A1 true AU2012351939A1 (en) 2014-07-10

Family

ID=48613248

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012351939A Abandoned AU2012351939A1 (en) 2011-12-16 2012-12-14 Angiotensins for treatment of fibrosis

Country Status (9)

Country Link
US (2) US20150057216A1 (enExample)
EP (1) EP2790716A4 (enExample)
JP (1) JP2015504870A (enExample)
KR (1) KR20150028761A (enExample)
CN (1) CN104302305A (enExample)
AU (1) AU2012351939A1 (enExample)
BR (1) BR112014014674A2 (enExample)
CA (1) CA2859573A1 (enExample)
WO (1) WO2013090833A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
AU2014268524A1 (en) * 2013-05-24 2015-12-03 Tarix Pharmaceuticals Ltd. Angiotensin peptides in treating Marfan Syndrome and related disorders
WO2015002903A1 (en) 2013-07-03 2015-01-08 Arizona Board Of Regents For The University Of Arizona Method for treating cognitive dysfunction
SG11201609593RA (en) * 2014-05-16 2016-12-29 Ultrast Inc Phase-shifting formulations
JP6666899B2 (ja) 2014-07-21 2020-03-18 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニヴァーシティー オブ アリゾナ Ａｎｇ−（１−７）誘導体オリゴペプチド、ならびにそれを使用および作製するための方法
US10183055B2 (en) 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
EP3204358B1 (en) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
EP3328384B1 (en) 2015-07-30 2020-07-29 Monash University Fibrotic treatment
JP2018530590A (ja) * 2015-10-14 2018-10-18 タリックス ファーマシューティカルズ リミテッド 表皮水疱症の処置のための方法及び組成物
WO2017218623A1 (en) * 2016-06-14 2017-12-21 Tarix Orphan Llc Methods and compositions for the treatment of epidermolysis bullosa
US11331368B2 (en) 2017-07-17 2022-05-17 Monash University Angiotensin receptor agonists and uses thereof
GB201913603D0 (en) 2019-09-20 2019-11-06 Vicore Pharma Ab New compounds
WO2021164723A1 (en) * 2020-02-20 2021-08-26 Lee Sheau Long Ginsenoside m1 as a modulator of angiotensin regulating enzymes and its use for treating diseases or conditions including symptoms caused by coronavirus
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
EP4085921A1 (en) * 2021-05-04 2022-11-09 CU-Pharmaceuticals UG Angiotensin-(1-7) in the treatment of sars-cov related diseases
GB202201723D0 (en) 2022-02-10 2022-03-30 Vicore Pharma Ab New use
WO2023152503A1 (en) 2022-02-10 2023-08-17 Vicore Pharma Ab Use of buloxibutid for the treatment of idiopathic pulmonary fibrosis
WO2025050228A1 (es) * 2023-09-08 2025-03-13 Pontificia Universidad Católica De Chile Composición farmacéutica que comprende un péptido o una combinación de péptidos agonistas de los receptores mas, at1 y at2
KR102743940B1 (ko) 2023-10-06 2024-12-19 엠브릭스 주식회사 안지오텐신 전환효소 2 및 Fc 절편을 포함하는 나노디스크 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU755225B2 (en) * 1997-12-12 2002-12-05 University Of Southern California Wound healing compositions
YU78601A (sh) * 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
US7064127B2 (en) * 2003-12-19 2006-06-20 Mount Sinai School Of Medicine Of New York University Treatment of hepatic fibrosis with imatinib mesylate
EP2163259B1 (en) * 2008-09-12 2012-06-13 Charité-Universitätsmedizin Berlin (Charité) Use of an Ang-(1-7) receptor agonist in acute lung injury

Also Published As

Publication number Publication date
CA2859573A1 (en) 2013-06-20
WO2013090833A1 (en) 2013-06-20
BR112014014674A2 (pt) 2017-06-13
US20160074466A1 (en) 2016-03-17
US20150057216A1 (en) 2015-02-26
KR20150028761A (ko) 2015-03-16
WO2013090833A8 (en) 2014-07-17
EP2790716A1 (en) 2014-10-22
JP2015504870A (ja) 2015-02-16
CN104302305A (zh) 2015-01-21
EP2790716A4 (en) 2015-06-10

Similar Documents

Publication Publication Date Title
US20160074466A1 (en) Angiotensins for treatment of fibrosis
EP2819687A1 (en) Compositions and methods for treatment of peripheral vascular disease
AU2018205186B2 (en) Angiotensin in treating brain conditions
AU2016207942B2 (en) Polymyxin derivative and uses thereof
US20180050079A1 (en) Angiotensin peptides in treating marfan syndrome and related disorders
US9763996B2 (en) Polymyxin derivative and uses thereof
US20230110554A1 (en) Methods and compositions for treatment of coronavirus infection
CA2940751C (en) Uses of an angiotensin (1-7) peptide for the delayed treatment of stroke
US8557958B1 (en) Compositions and methods for treatment of diabetes
AU2013315004A1 (en) Oral formulations of angiotensin
US20160296591A1 (en) Compositions and methods for treatment of bdnf-related conditions
US7691805B2 (en) Antimicrobial compounds
WO2015057403A2 (en) Compositions and methods for treatment of inflammatory bowel disease
AU2014332346A1 (en) Novel peptide compositions
US12240890B2 (en) Compositions and methods for treating and/or preventing pathogenic fungal infection and for maintenance of microbiome commensalism
WO2025122594A1 (en) Improved methods and compositions for the treatment of pemphigus or pemphigoid disease

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period